Koppert, Amoéba sign major biofungicide distribution agreement to advance crop protection

NETHERLANDS – Koppert, a global expert in sustainable crop protection, and Amoéba, a greentech innovator known for its patented amoeba-based bio-solutions, have signed a major commercial agreement aimed at advancing biological crop protection.

This agreement focuses on the innovative biofungicide solution created by Amoéba and follows the recent approval of Amoéba’s biocontrol active substance by the European Union Member States. The launch is expected in early 2026.

The biofungicide solution is based on the lysate of the amoeba Willaertia magna C2c Maky. It is an environmentally friendly product that protects crops against a broad range of diseases by targeting harmful fungi without affecting beneficial organisms. 

As a natural alternative to chemical fungicides, it helps farmers reduce chemical residues while preserving soil and ecosystem health.

The agreement grants Koppert exclusive distribution rights for five years for this biocontrol product, targeting vines and vegetable crops grown in both greenhouses and open fields across 18 European countries, including France, the Netherlands, Germany, Italy, as well as the United States. 

Koppert will distribute this biofungicide under its brand name, and the two companies will collaborate for the potential launch in Brazil.

Building on this foundation, both parties share a common vision for long-term growth and innovation.

A shared vision for growth

Martin Koppert, Chief Business Officer of Koppert, says: “This agreement marks a significant step forward in expanding our portfolio of innovative biological solutions.” 

He described the new biofungicide solution as an exciting addition that aligns perfectly with Koppert’s mission to support growers with sustainable and effective crop protection tools. 

“We look forward to a successful collaboration with Amoéba, bringing the benefits of this breakthrough technology to farmers across the world,” Martin added.

Koppert and Amoéba will evaluate the future production organization based on operational feedback and projected commercial scale-up.

The two companies will also begin discussions on the co-development of new biofungicide solutions for the crops covered by this agreement. 

By combining their respective product ranges and complementary expertise, they aim to deliver more effective and sustainable biological solutions that address growers’ needs and support healthier crops. 

These solutions will also have strong market potential and significant growth opportunities in the years to come.

This strategic milestone reinforces Koppert’s leadership in the biocontrol industry and highlights both companies’ shared commitment to advancing sustainable agriculture.

“The signing of this commercial agreement with the world leader in biocontrol is a key moment in the history of Amoéba,” Jean-François Doucet, Chief Executive Officer of Amoéba commented. 

He said the discussions had been productive and led to a mutually beneficial agreement, reaffirming the strong potential of their biofungicide solution and expressing optimism about the collaboration ahead.

Benoît Villers, Chairman of Amoéba’s Board of Directors, described the agreement with Koppert as a significant milestone for the company, highlighting their shared values and commitment to delivering healthy agricultural solutions. 

He emphasized that the deal marks the commercial validation of Amoéba’s biofungicide after years of research and development. 

Villers added that the expected value creation will position the company strongly for future growth, allowing it to explore new financial opportunities to support its industrial and commercial expansion.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.